This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,226.27 firm fixed-price delivery order is for the supply of RESTASIS 0.05% eye emulsion, a medication used to treat dry eye disease. The contract has a completion date of February 2, 2023. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This federal contract award, with ID SPE2DB22D2006|SPE2DB23FV9PW, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $14,815.58 firm fixed-price delivery order is for the supply of RESTASIS 0.05% eye emulsion, a prescription medication used to treat dry eye disease. The contract has a completion date of May 8, 2023 and was awarded on May 5, 2023. The contract is not designated as a...
This federal contract award, issued by the Defense Logistics Agency (DLA), was granted to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $7,922.21, is for the delivery of RESTASIS 0.05% eye emulsion, a specialty medication. The contract is a Firm Fixed Price Delivery Order, with a completion date of February 19, 2025. This award is not associated with a set-aside requirement. Amerisourcebergen holds a significant...
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,471.20 Firm Fixed Price Delivery Order contract is for the supply of RESTASIS 0.05% Eye Emulsion 30s, a prescription ophthalmic medication. The contract has an ultimate completion date of January 8, 2025. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This federal contract award, valued at $25,243.52, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of RESTASIS 0.05% eye emulsion, a specialty medication used for the treatment of dry eye disease. The contract is a Firm Fixed Price Delivery Order and does not have a set-aside designation, indicating it was awarded through open competition. AmerisourceBergen...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,528.08 Firm Fixed Price Delivery Order is for the supply of RESTASIS 0.05% Eye Emulsion, a specialty ophthalmic medication. The award is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,117.80 firm fixed-price delivery order is for the provision of RESTASIS 0.05% eye emulsion, a prescription ophthalmic medication. The contract has an ultimate completion date of March 17, 2025. This award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds...
This federal contract award, valued at $8,018.76, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp. for the delivery of RESTASIS 0.05% eye emulsion in 60-count packages. The contract is a Firm Fixed Price Delivery Order with a completion date of November 27, 2024. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary...
This federal contract award by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, is for the delivery of RESTASIS 0.05% Eye Emulsion 30s. The contract is a Firm Fixed Price Delivery Order with a ceiling value of $2,235.60 and a period of performance through January 27, 2025. The contract is not set aside for any specific business type. AmerisourceBergen is delivering this pharmaceutical product to support military treatment facilities,...
This federal contract award, valued at $18,411.17, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of RESTASIS 0.05% eye emulsion, a prescription medication used to treat dry eye disease. The contract is a Firm Fixed Price Delivery Order with a completion date of July 17, 2024. It is not designated as a set-aside contract. AmerisourceBergen holds a larger...